Metastatic Neuroendocrine Carcinoma

Includes index

Intro -- Foreword -- Contents -- Contributors -- Chapter 1: Introduction: Integration of APP into Urologic Oncology Practice -- Part I: Prostate Cancer -- Chapter 2: Overview and Active Surveillance of Prostate Cancer -- Introduction -- Epidemiology -- Risk Factors -- Signs and Symptoms -- PSA and Screening -- Diagnostic Evaluation -- Pathology -- Staging -- Risk Stratification -- Active Surveillance -- Bibliography -- Chapter 3: Monitoring and Managing Men Following Initial Treatment of Prostate Cancer -- Introduction -- Monitoring Categories -- Monitoring for Biochemical Recurrence

Risk Stratification and Additional Testing -- Evidence of Recurrence -- Conclusion -- References -- Chapter 4: Radical Prostatectomy and Survivorship After Radical Prostatectomy -- Radical Prostatectomy -- Survivorship after Radical Prostatectomy -- Urinary Recovery -- Sexual Recovery -- Works Cited -- Chapter 5: Multimodal Treatment Plans in Prostate Cancer -- Introduction -- Postoperative Radiation Therapy -- Genomics -- Bibliography -- Chapter 6: Radiotherapy for Prostate Cancer -- Radiotherapy Techniques -- External Beam Radiation Therapy -- Brachytherapy

Radiation Therapy Based on Prostate Cancer Staging -- Fractionation Schedules and Dosing -- Moderate Hypofractionation -- Ultrahypofractionated Regimens -- Accuracy -- Palliative Radiation Therapy -- Use of Androgen Deprivation Therapy (ADT) with Radiotherapy -- Unfavorable Intermediate-Risk Disease -- High-Risk and Very-High-Risk Disease -- Possible Side Effects -- Unique Toxicities: Recognition, Treatment, and Management -- Fatigue -- Urinary Toxicities -- Gastrointestinal Toxicities -- Sexual Dysfunction -- Stress Fractures -- Methods of Minimizing Adverse Effects

Survivorship after Radiotherapy -- Urinary Recovery -- Sexual Recovery -- Bowel Toxicity -- Secondary Malignancies -- Other Survivorship Considerations -- Assessing for Recurrence -- Conclusion -- References -- Chapter 7: Androgen Deprivation Therapy -- Introduction -- Mechanism of Action -- Regulation of Androgen Production -- Agents of Treatment -- Removal of Sources of Androgens -- Use of LHRH Agonists and GnRH Antagonists -- Antiandrogens: Nonsteroidal and Steroidal Antiandrogens -- Antiandrogen Withdrawal -- Side Effects Management -- Healthy Lifestyle -- Patient Counseling

Second-Line Hormone Manipulation -- Ketoconazole -- References -- Chapter 8: Second-Generation Androgen-Targeted Agents -- Second-Generation Androgen-Targeted Agents -- Usage, Indications, and Side Effects of Abiraterone, Enzalutamide, Apalutamide, and Darolutamide -- Abiraterone (ZYTIGA™, YONSA™) -- Enzalutamide (XTANDI™) -- Apalutamide (ERLEADA™) -- Darolutamide (NUBEQA™) -- Conclusion -- References -- Chapter 9: Chemotherapy and Prostate Cancer -- Introduction -- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) -- Metastatic Castration-Resistant Prostate Cancer (mCRPC)